GTMS
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, GTMS has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +22% growth.
Stocks Performance
GTMS vs S&P TSX Composite Index (Canada)
Performance Gap
GTMS vs S&P TSX Composite Index (Canada)
Performance By Year
GTMS vs S&P TSX Composite Index (Canada)
Greenbrook TMS Inc
Glance View
Greenbrook Tms, Inc. engages in the provision of transcranial magnetic stimulation, an FDA-cleared, non-invasive therapy for the treatment of major depressive disorder. The company is headquartered in Toronto, Ontario and currently employs 430 full-time employees. The company went IPO on 2018-10-03. The TMS therapy is a non-invasive therapy for the treatment of depressive disorder (MDD) and other mental health disorders. The TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. The firm's patient-focused, customer service model provides TMS therapy accessible to all patients through three business processes: Patient Inquiry; Patient Conversion; and Treatment Delivery. A course of TMS consists of 36 treatments and a course of treatment consist of an initial cortical mapping and motor threshold determination and treatment, daily treatment sessions and a subsequent motor threshold re-determination and treatment. The company operates through approximately 130 Company-operated treatment centers. The company operates across the States of North Carolina, South Carolina, Maryland, Delaware, Missouri, Illinois, and Ohio.
